IRADIMED (IRMD) CEO-linked trust sells 7,500 shares under plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
IRADIMED CORP insider Roger E. Susi, through the Phillip Susi 2008 Dynasty Trust, reported open‑market sales of 7,500 shares of common stock on April 20–21, 2026. Reported sale prices include $93.90, $93.14, $92.66, $91.65, $90.60 and $89.73 per share.
The filing notes these transactions were made under a Rule 10b5‑1 trading plan adopted on November 5, 2025, indicating they were pre‑scheduled. Post‑transaction line items show the trusts continuing to hold sizable indirect positions, with balances ranging from hundreds of thousands to over two million shares.
Positive
- None.
Negative
- None.
Insights
Planned, modest insider sales via trust; routine in scale.
The Form 4 shows 7,500 shares of IRADIMED CORP common stock sold in several open‑market trades by the Phillip Susi 2008 Dynasty Trust associated with CEO Roger E. Susi. Sale prices span $89.73 to $93.90 per share.
A key detail is that footnotes state these sales were executed under a Rule 10b5‑1 trading plan adopted on November 5, 2025. Such plans are pre‑arranged, so the timing signals routine portfolio management rather than a new discretionary decision tied to recent news.
Post‑trade figures show indirect trust holdings still in the hundreds of thousands to over two million shares per line item, suggesting the sold amount is small relative to the overall reported position. Overall, this looks like a planned, incremental reduction rather than a thesis‑changing move, so sentiment is neutral.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares ($694,124)
Net Sell
8 txns
Insider
Susi Roger E.
Role
CEO, President, Chairman
Sold
7,500 shs ($694K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,162 | $89.73 | $104K |
| Sale | Common Stock | 140 | $90.60 | $13K |
| Sale | Common Stock | 606 | $91.65 | $56K |
| Sale | Common Stock | 592 | $92.66 | $55K |
| Sale | Common Stock | 3,580 | $93.14 | $333K |
| Sale | Common Stock | 1,420 | $93.90 | $133K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,203,838 shares (Indirect, By Phillip Susi 2008 Dynasty Trust)
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $92.69 to $93.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $93.69 to $94.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $89.18 to $90.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $90.23 to $90.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $91.22 to $92.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $92.18 to $92.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Total shares sold: 7,500 shares
Sale price example: $93.90/share
Sale price example: $93.14/share
+5 more
8 metrics
Total shares sold
7,500 shares
Open-market sales on April 20–21, 2026
Sale price example
$93.90/share
Common stock sale on April 20, 2026
Sale price example
$93.14/share
Common stock sale on April 20, 2026
Sale price example
$92.66/share
Common stock sale on April 21, 2026
Sale price example
$91.65/share
Common stock sale on April 21, 2026
Sale price example
$90.60/share
Common stock sale on April 21, 2026
Sale price example
$89.73/share
Common stock sale on April 21, 2026
10b5-1 plan adoption date
November 5, 2025
Date reporting person adopted trading plan
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, pecuniary interest, beneficial ownership, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
pecuniary interest financial
"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein..."
beneficial ownership regulatory
"shall not be deemed an admission of beneficial ownership of all the reported shares..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or for any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider transactions did IRADIMED CORP (IRMD) report in this Form 4?
IRADIMED CORP reported that the Phillip Susi 2008 Dynasty Trust sold 7,500 shares of common stock in open‑market trades. These sales occurred on April 20–21, 2026, at prices between $89.73 and $93.90 per share, according to the Form 4 transaction details and footnotes.
Who is the reporting person in the IRADIMED CORP (IRMD) Form 4 filing?
The reporting person is Roger E. Susi, who is listed as CEO, President, Chairman and a more‑than‑10% owner of IRADIMED CORP. The reported transactions, however, were made indirectly through the Phillip Susi 2008 Dynasty Trust rather than through his direct personal holdings.
Were the IRADIMED CORP (IRMD) insider sales made under a Rule 10b5-1 plan?
Yes. A footnote states the sales were effected under a Rule 10b5‑1 trading plan adopted by the reporting person on November 5, 2025. Rule 10b5‑1 plans allow pre‑scheduled trades, which helps separate trading decisions from short‑term information or market movements.
What prices were received in the recent IRADIMED CORP (IRMD) insider stock sales?
The reported open‑market sales occurred at specific prices including $93.90, $93.14, $92.66, $91.65, $90.60 and $89.73 per share. Several transactions were executed in multiple trades, and the Form 4 reports weighted average sale prices for those multi‑trade executions.